CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Income Statement [Abstract]
Net revenues	$ 13,053	$ 5,208	$ 33,087
Cost of revenues	7,982	3,897	20,610
Gross profit	5,071	1,311	12,477
Operating costs and expenses:
Research, development and clinical trials	11,445	9,927	43,748
Sales and marketing	13,308	6,355	38,861
General and administrative	12,256	6,975	33,864
Total operating costs and expenses	37,009	23,257	116,473
Operating loss	(31,938)	(21,946)	(103,996)
Financial expenses, net	549	591	3,151
Loss before income tax expense	(32,487)	(22,537)	(107,147)
Income tax expense	2,950	736	4,434
Net loss	$ (35,437)	$ (23,273)	$ (111,581)
Basic and diluted net loss per ordinary share	$ (0.42)	$ (1.77)	$ (3.67)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	84,397,164	13,140,321	30,401,603